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Abstract
Our previous study reported that stemofoline (STF) exhibited a synergistic effect with chemotherapeutic
drugs in human multidrug-resistant (MDR) leukemic cells (K526/Adr) by inhibiting the function of Pglycoprotein, which is a membrane transporter that is overexpressed in several types of MDR cancers.
This study further investigated the effects of a combination treatment of STF and doxorubicin (DOX) in
vitro and in vivo. The combination treatment of 50 mg/kg of STF strongly enhanced the anti-tumor activity
of DOX in SCID-beige mice bearing K562/Adr xenografts without additional toxicity when compared to the
single treatment groups. Additionally, an examination of the proliferation markers (Ki67) and the apoptotic
marker (TUNEL) in tumor tissues in each group revealed that the combination therapy significantly
reduced Ki67 positive cells and increased apoptotic cells. From the in vitro experiments we also found
that this combination treatment dramatically induced G1 and G2M arrest in K562/Adr when compared to
a single treatment of DOX. STF treatment alone did not show any cytotoxic effect to the cells. These
results suggest that the accumulation of DOX enhanced by STF was sufficient to induce cell cycle arrest
in K562/Adr. These findings support our previous in vitro data and indicate the possibility of developing
STF as an adjuvant therapy in cancer treatments.
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Abstract
Our previous study reported that stemofoline (STF) exhibited a synergistic effect with chemotherapeutic drugs in
human multidrug-resistant (MDR) leukemic cells (K526/Adr) by inhibiting the function of P-glycoprotein, which is a
membrane transporter that is overexpressed in several types of MDR cancers. This study further investigated the effects of
a combination treatment of STF and doxorubicin (DOX) in vitro and in vivo. The combination treatment of 50 mg/kg of
STF strongly enhanced the anti-tumor activity of DOX in SCID-beige mice bearing K562/Adr xenografts without
additional toxicity when compared to the single treatment groups. Additionally, an examination of the proliferation
markers (Ki67) and the apoptotic marker (TUNEL) in tumor tissues in each group revealed that the combination
therapy significantly reduced Ki67 positive cells and increased apoptotic cells. From the in vitro experiments we also
found that this combination treatment dramatically induced G1 and G2M arrest in K562/Adr when compared to a single
treatment of DOX. STF treatment alone did not show any cytotoxic effect to the cells. These results suggest that the
accumulation of DOX enhanced by STF was sufficient to induce cell cycle arrest in K562/Adr. These findings support
our previous in vitro data and indicate the possibility of developing STF as an adjuvant therapy in cancer treatments.
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Introduction
Leukemia is a cancer that affects the blood and
bone marrow, the spongy center of bones where
blood cells are formed. Leukemia treatment usually
involves chemotherapy, bone morrow implantation and
radiotherapy (Baruchel et al., 2009; Matsumura, 2009).
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder of hemopoitic stem cells. The incident rate
of CML in males has been reported to be higher than
the rate for females (male/female ratio is 1.3-1.5:1)
(Quintas-Cardama and Cortes, 2006; Mendizabal et al.,
2013). There has been some improvement in survival
rates since the introduction of therapeutic drugs including
the anthracyclines (doxorubicin, epirubicin), the vinca
alkaloids (vinblastine, vincristine) and methotrexate,
L-asparaginase and alkylating agents (Norgaard et al.,
2004). Chemotherapy for CML treatment uses one or
usually at least two of the above-mentioned chemical
substances. Such treatments not only destroy or reduce
tumor cell growth but also increase the 5-year survival rates
for cancer patient. However, resistance to anti-neoplastic

drugs can develop in several types of cancer patients
who have taken chemotherapy over long periods of time
(Tiwari et al., 2011; Binkhathlan and Lavasanifar, 2013).
Chemo-resistance or multidrug resistance (MDR)
is a major problem in cancer treatments. The various
mechanisms of MDR include overexpression of drug
transporters, an increase in detoxification mechanisms
along with an induction of DNA repairing enzymes,
and altered drug targets (deletion, translocation and
amplification of drug target) (Gottesman et al., 2002; Fojo
and Menefee, 2007; Lage, 2008). The causes of death in
leukemic patients are infection, loss of muscle control and
heart failure. However, several studies have described the
increased P-gp expression after the initial chemotherapy
treatment that has repeatedly been linked to poor outcomes
in some forms of leukemia (Marie et al., 1996; Leonard
et al., 2003). Doxorubicin (DOX) is an effective form of
chemotherapy against both hematological malignancy and
solid tumors. DOX exhibited higher efficacy on leukemic
patient by reduction of blast cells in blood circulation.
Anti-tumor mechanisms of DOX are achieved by the
induction of free radicals, which are linked to DNA
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damage, and inhibition of DNA and RNA synthesis by
inhibition of topoisomerase II (Rabbani et al., 2005;
Rogalska et al., 2008; Szwed et al., 2016). However,
DOX has been shown to give rise to the development
of drug resistance, which might be due to an increase in
P-glycoprotein (P-gp) expression (de Moraes et al., 2013).
Many P-gp inhibitors have been reported, such
as the first generation drugs verapamil, quinidine
and cyclosporine A, and the second generation drugs
dexverapamil, emopamil and PSC833. Therefore,
researchers have tried to identify the third-generation of
P-gp inhibitors (with prolonged half-life and reduction
of toxicity) from plants or natural products. These agents
are currently being studied in clinical trials (Krishna and
Mayer, 2000; Leonard et al., 2003). We have focused on
natural compounds as inhibitors of P-gp to enhance the
efficacy of anticancer drugs against MDR cancer cells.
Many natural product P-gp inhibitors have been reported,
including curcumin (Anuchapreeda et al., 2006; Limtrakul
et al., 2007), kuguacin J (Pitchakarn et al., 2012) and
calidonine (El-Readi et al., 2013).
Stemona plants that are found in East and South-east
Asia are important herbal plants with various medicinal
and pharmacological properties. Plant extracts obtained
from Stemona tubulosa, S. sessilifolia and S. japonica
have been reported for their antitrussive activities in
mouse model studies (Hu et al., 2009). The S. tubulosa
extract has been reported to have an anti-inflammatory
effect of the lungs in cigarette smoke-induced pulmonary
inflammation both in vitro and in vivo (Lee et al., 2014;
Lim et al., 2015). The S. tubulosa and S.collinsae extracts
have been reported to have anti-proliferative effects on the
medullary thyroid carcinoma cell line (Li et al., 2007).
However, the activity of Stemona plant extracts against
drug resistant cancer cells has not yet been reported. In our
previous studies we reported that the extract of Stemona
burkillii could enhance the chemotherapeutic sensitivity
in human MDR cervical carcinoma (KB-V1) cells
(Chanmahasathien et al., 2011a; Pyne SG et al., 2017). We
then purified and identified the active compound identified
as the Stemona alkaloid stemofoline (STF).
In our previous studies we found that STF showed
significant synergistic effects with conventional anticancer agents against KB-V1 and human MDR leukemic
cells (K526/Adr). STF inhibited P-gp function leading to
increases of P-gp fluorescent substrates (calcein-AM and
rhodamine 123) and [14C]-DOX intracellular accumulation
in KB-V1 and K562/Adr cells (Chanmahasathien et al.,
2011a; Umsumarng et al., 2013; Umsumarng et al.,
2015). The biochemical mechanism of STF could be that
it reverses the MDR cancer phenotype by inhibition of
P-gp function via direct interaction with the substrate
binding domain but by without affecting P‑gp expression
(Chanmahasathien et al., 2011b). However, the MDR
reversal property of STF in an animal model has not yet
been demonstrated. In this study, we further investigated
the effect of the combination treatment of STF and DOX
in an animal model. We first investigated the acute toxicity
of STF by acute toxicity testing and studied the MDR
modulating property of STF in MDR leukemic cells in
a xenograft model. Next, we determined the mechanism
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for synergistic effect of STF and DOX in MDR leukemic
cells in vitro.

Materials and Methods
Stemofoline extraction and isolation
STF was isolated from Stemona burkillii root extract
and its structure is shown in Figure 1. Dried root powders
were extracted with a solution of 95% of ethanol three
times at room temperature. The ethanolic extract was
combined and evaporated using a rotary evaporator. STF
was purified as previously described (Sastraruji et al.,
2010; Chanmahasathien et al., 2011a; Sastraruji et al.,
2012).
Cells and cell culture
K562/Adr (human MDR leukemic cell line, CML)
was purchased from RIKEN Cell Bank (Tsukuba,
Ibaraki, Japan). K562 (human drug sensitive leukemic
cell line) was purchased from The American type Culture
Collection (ATCC, Manassas, VA, U.S.A.). Both cell
lines were maintained and cultured in a 37°C humidified
atmosphere comprised of 5% CO2 in RPMI-1640 (Nissui
Pharmaceutical Co., Ltd., Taito-ku, Tokyo, Japan) with
10% fetal bovine serum (FBS), 5 mm L-glutamine, 50
IU/mL penicillin and 50 g/ mL streptomycin. When the
cells reached 70–80% confluence, they were harvested
and plated either for subsequent passages or for drug
treatments. K562/Adr cells were routinely maintained
in RPMI-1640 culture medium containing 700 nM of
doxorubicin (DOX, Sigma Chemical Co., St. Louis, MO,
U.S.A.) and grown in a drug-free medium for at least two
days before the experiment.
Animals
All animal experiments were performed under
protocols approved by the Committee of Animal Care
and Use of Saitama University. Eight-week-old male
ICR mice and 6-week-old male SCID-Beige mice were
purchased from Charles River Japan, Inc. (Atsugi, Japan)
and housed in plastic cages with bedding consisting of
hardwood chips in an air-conditioned room at 23±2oC and
at 55±5% humidity with a 12 h light/dark cycle. Diet and
autoclaved water were available ad libitum.
Acute toxicity testing
The acute toxicity of STF was evaluated using
eight-week-old 5 male ICR mice. The ICR mice were
intraperitoneally (i.p.) injected with STF (50 mg/kg BW)
according to OECD 420 guidelines. Mice morbidity and
mortality were recorded daily. After treatment for two
weeks, the surviving mice were sacriﬁced and LD50 values
were calculated. Mice serum samples were collected
to investigate liver function by determining alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels. Renal function was tested by determination
of blood urea nitrogen (BUN) and creatinine levels.
Internal organs (liver, spleen, heart, lungs and kidneys)
were measured and gross examination was observed on
abnormal lesions. Consequently, sections of the internal
organs were fixed in 10% of formaldehyde in PBS. These
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sections of internal organs were prepared for paraffin
embedding. The paraffin sections were then stained
by H and E. Pathological evaluation was conducted
by a Veterinarian Pathologist. The acute toxicity was
determined by mice body weight, mice survival rate,
gross examination and histopathological examination
of internal organs and the data were compared with the
references values.
Effect of STF on DOX sensitivity in a K562/Adr xenograft
model
Human multidrug resistant leukemic cell (K562/
Adr) xenograft model was used for an investigation of
the MDR reversing property of STF on DOX sensitivity.
Six-week-old male SCID-beige mice (20 mice) were
implanted with K652/Adr cells (5.0 x 10 6 cells)
subcutaneously at the flank area of the mice (Beider
et al., 2014). The tumors on the flank area of the mice
were palpated every day. As soon as the tumors reached
100-200 mm3 in volume, the mice were divided into 4
groups: 1) vehicle control; 0.9% NaCl; IP 2) STF 50 mg/
kg BW; IP, 3) DOX 2 mg/kg BW; IV and 4) DOX 2 mg/
kg BW; IV plus STF 50 mg/kg BW; IP, respectively. For
the combination treatment group, 50 mg/kg BW of STF
was administered for 30 minutes before DOX was applied.
These treatments were applied every 4 days for 16 days.
The mice that bore tumors were measured every 3 days
and their weights were measured every 4 days. After
which, all mice were sacrificed and primary tumors were
removed and measured in terms of weight and volume
(formula; axis 1 x axis 2 x axis 3) x 0.52 (Pitchakarn
et al., 2012; Punfa et al., 2014). Internal organs (liver,
spleen, heart, lungs and kidneys) were inspected for
abnormal lesions. Sections of the primary tumors and
internal organs were then fixed in 10% of formaldehyde
in PBS. These sections of the internal organs were used
to prepare paraffin embeds. Paraffin sections were stained
with H and E. Pathological evaluations were conducted by
Veterinarian Pathologist. Tumor sections were processed
for H and E, Ki67 immunohistochemistry staining and
terminal deoxynucleotidyl transferase mediated dUTP
nick end labeling (TUNEL) assay.
Immunohistochemistry
For Ki67 immunostaining, paraffin-embedded
specimens were sectioned (5 µm) and stained with Ki67
antibody (clone SP6) (Acris Antibodies GmbH, Herford,
Germany) and then with anti-rabbit secondary antibody
and avidin–biotin complex (Vectastatin Elite ABC kit;
Vector Laboratory, Burlingame, CA). After which, the
binding sites were visualized with diamino-benzidine.
The sections were then counterstained lightly with
hematoxylin for microscopic examination.
TUNEL assay
Apoptotic index values were determined by TUNEL
assay. The assay was performed using ApopTag®
Peroxidase In Situ Apoptosis Detection Kit (Merck
millipore Billerica, Massachusetts, USA).

Chemo-sensitivity testing by MTT colorimetric assay
Cell viability of each leukemic cell line was measured
using the MTT assay. Drug sensitive human leukemic
cells (K562) and human MDR leukemic cells (K562/Adr)
were plated in a 96-well-plate at a concentration 2.0×103
cells/well. After 24h, the cells were treated with 0-40 µM
of DOX with or without 5 µM of STF. Cell lines were
incubated under a temperature of 37oC at 5% of CO2.
After 48 hours of treatment, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT, Sigma Chemical
Co., St. Louis, MO, U.S.A.) was added to each well for
4h. RPMI-1640 medium was then removed and 200 μL of
DMSO (Wako Pure Chemical Ind., Ltd., Chuo-ku, Osaka,
Japan) was added to the specimen. Each leukemic cell line
was incubated at 37oC, 5% CO2 for 4 h. Cell viability was
assessed by determining the mean of MTT colorimetric
assay. In each experiment, determinations were carried
out in triplicate. IC50 value of each cell line was calculated.
Apoptosis analysis by annexin V and propidium iodine
(PI) staining
K562/Adr cells were plated in a 6-well plate at a
concentration of 5.0×105 cells/well. After 24h, the cells
were treated with various concentrations of DOX (0-5
µM) in the absence or presence of 5 µM of STF for 48 h.
Cells were then collected and washed twice with ice-cold
PBS. The cell line was stained with annexin V-FITC and
PI according to the manufacturer’s instructions using the
annexin V-FITC apoptosis detection kit (BioVision Inc.,
Milpitas, CA, U.S.A.). Apoptotic cells were detected
by flow cytometry. Annexin V-positive cells were
considered indicative of early apoptosis. Both annexin V
and PI-positive cells were considered indicative of late
apoptosis.
Cell cycle analysis by propidium iodine (PI) staining
K562/Adr cells were plated in a 6-well-plate at a
concentration of 5.0×105 cells/well. After 24hrs, the cells
were treated with various concentrations of DOX (0-5 µM)
with or without 5 µM of STF for 48 hours. Leukemic cells
were collected and washed twice with ice-cold PBS. The
cell line was fixed with 70% cold ethanol for 30 minutes
and incubated for 30 minutes by 0.25 mg/mL of RNase
A in 1.12% of sodium citrate buffer. Finally, the cell
line was stained with PI for 30 minutes. Cell cycling was
performed by flow cytometry.
Statistical analysis
All in vitro experiments were performed in at least
triplicate to confirm reproducibility. Statistical analyses
were performed with mean ±S.D. values using one-way
ANOVA, the Bonferroni correction and Dunnett’s test.
Statistical significance was determined at p < 0.05,
p< 0.01 or p< 0.001.

Results
Acute toxicity study of STF
The acute toxicity study of STF was evaluated using
five eight-week-old male ICR mice. The ICR mice were
i.p. injected with highest solubility of STF (50 mg/kg
Asian Pacific Journal of Cancer Prevention, Vol 19

3535

Sonthaya Umsumarng et al

Table 1. Effect of STF on Acute Toxicity in Animal Models
Parameters

Mouse#1

Mouse#2

Mouse#3

Mouse#4

Mouse#5

Mean±SD

Ref.

Mice BW (g) (start)

33.5

31.88

32.4

34.1

33.8

33.14±0.95

30.50±2.60a

Mice BW (g) (end)

31.62

32.62

32.51

33.06

33.1

32.58±0.60

32.50±3.40a

Survival rate (%)

100

100

100

100

100

100.00±0.00

-

Liver (g)

2

1.84

1.95

2.01

2.05

1.97±0.08

1.878±0.248a

Spleen (g)

0.14

0.13

0.13

0.14

0.16

0.14±0.01

0.145±0.021a

Heart (g)

0.22

0.23

0.23

0.24

0.24

0.23±0.01

0.175±0.023a

Rt. Kidney (g)

0.4

0.37

0.43

0.39

0.44

0.41±0.03

0.441±0.062a

Lt. Kidney (g)

0.4

0.31

0.41

0.35

0.4

0.37±0.04

ALT (U/L)

15

15

20

13

14

15.40±2.70

37.0±9.10b

AST (U/L)

124

90

60

94

83

90.20±23.03

100.00±14.60b

BUN (mg/dL)

26

27

26

30

28

27.40±1.67

28.54±3.16b

Creatinine (mg/dL)

0.3

0.3

0.3

0.3

0.3

0.30±0.00

0.43±0.18b

ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BUN, Blood urea nitrogen; aCharles River Laboratories Tech. 1986; bLaurie el
al., 2003.

detected. In addition, there is no histological lesion was
observed in H and E staining of liver, spleen, heart, lung
and kidney of all the treatment mice (Figure 2E).
H and E, Ki67 and TUNEL staining are shown
in Figure 3A. The Ki67 labeling index value was
significantly reduced in the combination treatment group
(Figure 3B) and TUNEL-positive cells of the transplanted
tumor tissues were shown to have significantly increased
in the combination treatment group (Figure 3C). These
results could suggest that the treatment of STF and DOX
revealed a significant synergistic effect by reducing
cell proliferation and inducing apoptosis in K562/Adr
transplantation SCID-beige mice.

Figure 1. Structure of STF
BW) for 2 weeks. Our result shown that all mice were not
observed acute toxicity. There were no differences in the
body weight and internal organ weight when compared
to the reference materials (Table 1).

STF-enhanced sensitivity of MDR leukemic cells to
chemotherapeutic drug
We examined the MDR reversing property of STF and
DOX co-administration in K562/Adr (MDR leukemic
cells) and K562 (drug sensitive cells) cell lines. We found
that co-administration of STF and DOX significantly
induced growth inhibition in a dose dependent manner
when compared with DOX single treatment in K562/
Adr (p<0.001). This modulating effect was not found
with a similar administration of DOX and STF to K562
cells (Figure 4A and B). Moreover, we demonstrated that
treatment K562 and K562/ADR with STF 50 µM for 48h
were not show cytotoxic to K562 and K562/Adr cells

STF-enhanced sensitivity of MDR leukemic cells to
chemotherapeutic drug in vivo
Our results found that co-administration of DOX+STF
reduced the tumor volume of K562/Adr cells implanted
in the back area of SCID-Beige mice when compared
administration with the control (p=0.3827), with STF
(p=0.1371) and with DOX (p=0.4091) (Figure 2A and B).
Moreover, tumor weight also significant reduced when
the mice was co-administration with DOX+STF when
compare with control, STF and DOX (Figure 2C). An
adverse effect on the body weight (Figure 2D) and internal
organs (Table 2) of the host SCID-Beige mice was not

Table 2. Effect of Treatment on the Body Weight and Internal Organs of Host SCID-Beige Mice
Parameters

Vehicle control group

STF treated group

DOX treated group

DOX+STF treated group

Mice BW (g) (start)

24.10±1.35

24.03±1.16

25.97±1.06

24.23±1.58

Mice BW (g) (end)

22.20±1.84

22.73±2.32

21.87±1.62

20.83±1.97

Survival rate (%)

100

100

100

100

Liver (g)

1.03±0.15

1.22±0.16

1.08 ±0.27

1.07±0.12

Spleen (g)

0.04±0.02

0.05±0.01

0.03±0.01

0.02±0.01

Heart (g)

0.13±0.02

0.13±0.02

0.15±0.05

0.10±0.03

Rt. Kidney (g)

0.24±0.02

0.23±0.05

0.20±0.02

0.17±0.03

Lt. Kidney (g)

0.18±0.04

0.23±0.07

0.19±0.02

0.19±0.02

Tumors weight (g)

1.7±0.03

2.05±0.67

2.03±0.09

0.99±0.17
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Figure 2. Potentiation of Antitumor Effects of DOX by STF in K562/Adr Xenograft Model. Mice were treated with
saline (control); STF alone at 50 mg/kg; DOX alone at 2 mg/kg; doxorubicin at 2 mg/kg plus STF 50 mg/kg (STF was
given 30 minutes before DOX administration). Tumor volumes were monitored during the experiment by a Vernier
caliper (D0-D16) (A). After scarification (day 16) time, tumors were removed for measure tumor volume (B) and
tumor weight (C). Changes in body weight during the experiment were recorded (D). Microphotographs of H&E
sections of internal organs from SCID-Beige mice after treatment with saline (control); STF alone at 50 mg/kg; DOX
alone at 2 mg/kg; doxorubicin at 2 mg/kg plus STF 50 mg/kg (STF was given 30 minutes before DOX administration).
Mice were sacrificed for pathologic examination 4 day after the last administration. Original magnification (x20) (E)
Asian Pacific Journal of Cancer Prevention, Vol 19
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Figure 3. Tumor Masses were Cross-Sectioned and Fixed in 10% Formalin Buffer and Prepared in Paraffin Embed
Block. They were then stained with H and E and immunohistochemistry (A); (Ki67) proliferation marker and apoptotic
marker (TUNEL). % of proliferation marker (Ki67)-positive cells (B) and % of apoptotic marker (TUNEL)-positive
cells (C) were analyzed using Image J software.

Figure 4. MDR Modulation Effect of STF on DOX Sensitivity in K562/Adr (A) and K562 Cell Lines (B) was
determined. The co-administration of DOX (0-40 µM) with or without STF was performed by MTT colorimetric
assay for 48 hrs. The mean value from three independent experiments is shown and error bars indicating SD (n = 3)
are shown as ***p <0.001 versus DOX single administration at each indicated concentration.
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Figure 5. STF Enhanced Sensitivity of K562/Adr Cells to DOX. The graphs represent living cells (A), early apoptosis
(B) and late apoptosis cell populations (C). K562/Adr cells were treated with various concentrations of DOX (0-5 µM)
with or without 5 µM of STF for 48 hrs. After treatment, K562/Adr were washed twice with PBS and stained with
annexin V and propidium iodide (PI). Apoptosis induction was determined by flow cytometry. The mean values from
three independent experiments are shown and error bars indicate SD (n = 3).
(Figure 4C). The results suggested that STF could enhance
the sensitivity of the MDR leukemic cell line to DOX.
Enhanced sensitivity of MDR leukemic cells to
chemotherapeutic drug by apoptosis and cell cycle arrest
induction
Next, we investigated the effect of the STF and DOX
co-administration induced program of cell death in K562/
Adr cells. The results indicated that co-administration of
DOX and STF slightly revealed apoptosis induction in
K562/Adr cells when compared to a single administration
on both early and late apoptosis (Figure 5A-C). Next,

cell-cycle determination in MDR leukemic cells was
performed to confirm that the growth inhibition was due
to the action of DOX. It was found that co-administration
treatment of DOX and STF significantly induced G2/M
phase arrest in K562/Adr cells at co-administration of
DOX 1 µM (p <0.05) and 5 µM (p <0.001) when compared
to the single administration (Figure 6A-C). The results
suggested that the co-administration treatment of DOX
and STF induced G1 and G2/M phase arrest.
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Figure 6. STF Enhanced Sensitivity of K562/Adr Cells to DOX. The graphs represent G1 (A), S (B) and G2/M phase
distribution (C). K562/Adr cells were treated with various concentrations of DOX (0-5 µM) with or without 5 µM of
STF for 48 hrs. After treatment, K562/Adr cells were washed twice with PBS and stained with propidium iodide (PI).
Cell cycle phase distribution was determined by flow cytometry. The mean value from three independent experiments
is shown and error bars indicate SD (n = 3). *p <0.05, **p <0.01 and ***p <0.001 versus DOX single administration
at each indicated concentration.

Discussion
P-gp is a member of the transport protein superfamily
called ATP-binding cassette (ABCB1/P-gp). It is a
170-kDa transmembrane glycoprotein, which plays a
major role in multidrug resistance (MDR) in various forms
of cancer, such as in human cervical carcinoma cells, breast
cancer adenocarcinoma cells and human leukemic cells
(Acharyya et al., 2012). Moreover, it has a wide-spectrum
substrate capacity, including for several chemotherapeutic
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drugs (anthracyclin, vinca alkaloids and paclitaxel) and
fluorescence dyes (Calcein-AM and rhodamine 123).
Therefore, P-gp can be the target for cancer treatment in
order to enhance the efficacy of chemotherapeutic drugs
in MDR cancer patients. Chemo-sensitizers or P-gp
modulators are agents that abrogate the drug accumulation
defect present in P-gp-expressing cancer cells. The
magnitude of the chemo-sensitizer effects could be
determined by comparing the IC50 values for a cytotoxic
drug in the absence and presence of a relatively non-
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toxic, fixed concentration of the chemo-sensitizer
(Marie et al., 1996). Verapamil (VER) and cyclosporine
A (CSA) have been reported to be P-gp modulators in
P-gp-mediated MDR cancer cells (Sharom et al., 1999;
Krishna and Mayer, 2000), but they have limitations
in clinical use due to their side effects (Ford and Hait,
1990). This has generated the need to search for new
effective MDR modulators that have been isolated from
natural products and that do not produce adverse side
effects. A previous study reported that Stemona curtisii
root extract, which contains Stemona alkaloids (Greger,
2006), modulated P-gp activity in human cervical cancer
cells and the KB-V1 cell line (high P-gp expression).
However, this was not the case with Multidrug resistant
related protein-1 (MRP-1) activity in the MRP1-HEK293
cell line (high MRP-1expression). The results obtained
from the present study strongly supported the finding
that the Stemona plant extract may show a promising
role as a P-gp modulator. In 2011, the MDR reversing
property of three Stemona alkaloids (stemocurtisine; STC
oxystemokerrine; OST and stemofoline; STF) isolated
from Stemona burkillii (Chanmahasathien et al., 2011a)
were studied and it was found that STF had the most potent
effect on enhancing cancer drug sensitivity against human
MDR cervical carcinoma cells (Chanmahasathien et al.,
2011b). However, one limitation of natural compounds
is that the variations of concentrations of the active
compounds depend on the area of cultivation or the plant
species. To solve this problem, semi-synthetic methods
can increase the yields of active compounds and improve
the compound efficacy by side chain modification of the
parental core structure.
Stemona plants are comprised of three genus; Stemona,
Croomia and Stichoneuron. The underground parts of the
plant, roots and rhizomes have been used in Ayurvedic
medicines with broad applications in Thailand, China and
Japan. It has been reported that Stemona collinsiae root
extract exhibited antineoplastic properties (Rungrojtrakool
et al., 2012) and biological activity against human herpes
virus (Akanitapichat et al., 2005). The investigation of
the anti-cancer properties of Stemona alkaloids obtained
from Stemonaceae holds significant promise for the
development of more effective chemotherapeutic or
adjuvant agents in cancer treatments. Previous studies
point out the significant functional group that might
regulate the P-gp modulating effect of Stemona alkaloids
(Umsumarng et al., 2017). STF is a major alkaloid
present in Stemona curtisii and Stemona burkillii, which
is found in the southern and northern parts of Thailand,
respectively (Kongkiatpaiboon et al., 2011). Additionally,
DSTF is a major alkaloid of Stemona collinasae, which is
found in the eastern part of Thailand (Kongkiatpaiboon
et al., 2011). Recently, it has been reported that Stemona
alkaloids isolated from Stemona curtisii could inhibit P-gp
activity, whereas other alkaloids purified from Stemona
javanica and Stichonueron halabalesis did not exhibit this
property (Umsumarng et al., 2017). It could be concluded
that alkaloid variations in the different Stemona species
have an influence on their P-gp modulating activity.
The present study supported the findings of previous
studies that stated that the type of Stemona alkaloids

included in Stemona plants can be used to indicate their
chemosensitizing ability (Chanmahasathien et al., 2011a;
Chanmahasathien et al., 2011b; Umsumarng et al., 2017).
In the animal experiments, STF, a major alkaloid found
in Stemona burkillii and Stemona curtisii that strongly
exerts MDR reversal property, was selected to determine
its chemosensitizing effect in vivo. Acute toxicity testing
of STF in ICR mice was determined and it was found
that all ICR mice could survive after i.p. injection of STF
(50 mg/kg BW). Notably, there no lesions were found in
the heart, lungs, liver, kidneys, or spleen as determined
by gross and histopathology examinations. Furthermore,
blood chemistry analysis showed that ALT, AST, BUN
and creatinine levels were normal suggesting that the
function of the liver and kidneys in the STF-treated mice
was not altered. The results indicate that 50 mg/kg BW
of STF was found to be safe and can be utilized in further
investigations. The P-gp modulating effect of STF was
next evaluated in K562/Adr bearing SCID-beige mice.
Twenty male SCID-beige mice were subcutaneously
injected with K562/Adr cells in the flank area. The tumor
size was measured every day. As soon as the tumor
volume reached 100-200 mm3, the mice were divided
into 4 groups: 1) vehicle control; 0.9% NaCl; I.P., 2) STF
treatment (50 mg/kg BW; I.P.), 3) DOX treatment (2 mg/kg
BW; IV) and 4) combination of DOX (2 mg/kg BW; IV)
and STF (50 mg/kg BW; I.P.). After which, the treatment
was initiated. Unfortunately, due to certain technical
errors, tumor growth was observed in only in 12 of 20
transplanted-mice. Consequently, tumors were identified
in three mice in each group. The co-administration of
DOX and STF was found to clearly reduce tumor size
when compared with the vehicle control group (p=0.3827),
STF (p=0.1371) and DOX (p=0.4091). The survival rate
of SCID-Beige mice was 100%. The adverse effects on
the body weight and internal organs of each group were
not found to be different. Immunohistochemistry analyses
found that the combined treatment significantly reduced
the Ki67 proliferation marker (p<0.01) and induced
apoptosis (TUNEL) (p<0.001) when compared to the
DOX-treated group. Tumor growth did not differ in the
single treatment of STF when compared to the control
group. These results indicate that STF itself did not affect
tumor growth, but STF was able to enhance the efficacy of
DOX in K562/Adr-xenograft SCID-Beige mice. It can be
concluded that STF could modulate P-gp-mediated MDR
leading to an increased chemotherapeutic drug response
in the animal model.
We have confirmed that STF and DOX co-administration
induced program cell death by apoptosis analysis via flow
cytometry. It was found that co-administration of DOX
and STF initiated apoptosis induction in K562/Adr cells
when compared to a single administration in both early
and late apoptosis. The mechanism of DOX is a cell cycle
non-specific agent. It could produce reactive oxygen
species (ROS) and inhibit topoisomerase II leading to
DNA damage and chromatin aggregation (Rabbani et al.,
2005). However, in treatments of 48 hours, STF could
inhibit P-gp function leading to increasing intracellular
DOX accumulation. The DNA damage response
mechanism of the cancer cells may be halted in some
Asian Pacific Journal of Cancer Prevention, Vol 19
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cell-cycle phases by repairing the DNA. However, if
cancer cells were unable to repair DNA, programed cell
death could be induced by apoptosis signaling.
Cell-cycle arrest in MDR leukemic cells was
performed to confirm that the growth inhibition was due
to the action of DOX by flow cytometry. It was found
that the co-administration treatment of DOX and STF
significantly induced G2/M phase arrest in K562/Adr cells
through a co-administration of DOX 1 µM (p <0.05) and 5
µM (p <0.001) when compared to a single administration.
The results suggest that the co-administration treatment of
DOX and STF induced G1 and G2/M phase arrest. Notably,
DOX is the drug of choice to treat leukemic patients. DOX
produces ROS and inhibits topoisomerase II leading to
chromatin aggregation (Rabbani et al., 2005). It can arrest
cancer cells in all cell-cycle phases and induces cell death.
The results indicated that the DOX treatment caused cell
accumulation at the G2/M phase, while the accumulation
was shifted to sub-G1 and S populations when the cells
were co-treated with STF. However, the cytotoxicity and
growth inhibition might be due to the anti-cancer drugs
that accumulated in the MDR cells and were stimulated by
the STF. These results suggest that the compounds were
able to enhance the drug sensitivity via the modulation
of P-gp.
The present study provides scientific data on the
biochemical mechanism of STF on P-gp overexpressing
of MDR cancer cells. STF may be a candidate as a
P-gp modulator as its toxicity is low and it produces no
noticeable adverse effects. These compounds could be
developed and used in combination with the conventional
therapy of P-gp overexpressing in MDR cancer patients.
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